GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting
ATLANTA, GA - June 17, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today highlighted new clinical data presented at the 2025 European Hematology Association (EHA) Hybrid Congress, which took place June 12-15 in Milan, Italy.
The data were featured in a poster presentation by Alexey V. Danilov, M.D., Ph.D., Associate Director of the Toni Stephenson Lymphoma Center and Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope Comprehensive Cancer Center in Duarte, California. The poster titled 'MVA-Based GEO-CM04S1 Vaccine Results in Improved Cellular Immune Response in Patients with Chronic Lymphocytic Leukemia (CLL) Compared with mRNA-Based Vaccine: Initial Results of a Phase II Randomized Study', detailed findings from an ongoing randomized Phase 2 clinical trial (NCT05672355), and highlighted interim results showing superior cellular immune responses induced by GEO-CM04S1 compared to those induced by an authorized mRNA-based COVID-19 vaccine in CLL patients, a population known to exhibit suboptimal protective responses to COVID-19 and other vaccines due to immune dysfunction.
Key Findings from the Study
'These findings reinforce the clinical and immunologic advantages of our multi-antigen approach,' said Kelly T. McKee, Jr., M.D., Chief Medical Officer of GeoVax. 'GEO-CM04S1's robust cellular response in immunocompromised individuals, especially patients with hematologic malignancies like CLL, provides further validation of our MVA platform's potential to address critical gaps in COVID-19 protection.'
About GEO-CM04S1
GEO-CM04S1 is a next-generation COVID-19 vaccine based on a synthetic Modified Vaccinia Ankara (MVA) vector. Unlike single-antigen vaccines, it expresses both the Spike (S) and Nucleocapsid (N) proteins of SARS-CoV-2, aiming to provide broader, cross-reactive, and more durable immunity. The vaccine is currently being evaluated in three Phase 2 clinical trials across various patient populations, including immunocompromised individuals and healthy adults.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
[email protected]
678-384-7220
Investor Relations Contact:
[email protected]
212-698-8696
Media Contact:
Jessica Starman
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
CDC shooter's motive revealed — documents show discontent with COVID-19 vaccines
ATLANTA (AP) — The man who fired more than 180 shots with a long gun at the headquarters of the U.S. Centers for Disease Control and Prevention broke into a locked safe to get his father's weapons and wanted to send a message against COVID-19 vaccines, authorities said Tuesday. Documents found in a search of the home where Patrick Joseph White lived with his parents 'expressed the shooter's discontent with the COVID-19 vaccinations,' Georgia Bureau of Investigation Director Chris Hosey said. White, 30, had written about wanting to make 'the public aware of his discontent with the vaccine,' Hosey said. Advertisement 3 Documents found in a search of the home where CDC shooter Patrick Joseph Smith lived with his parents revealed his discontent with the COVID-19 vaccinations. AP White also had recently verbalized thoughts of suicide, which led to law enforcement being contacted several weeks before the shooting, Hosey said. He died at the scene Friday of a self-inflicted gunshot wound after killing a police officer. Asked about threats based on misinformation regarding the CDC and its vaccine work, FBI Special Agent Paul Brown said Tuesday: 'We've not seen an uptick, although any rhetoric that suggests or leads to violence is something we take very seriously.' Advertisement 'Although we are tracking it, we are sensitive to it, we have not seen that uptick,' said Brown, who leads the FBI's Atlanta division. The suspect's family was fully cooperating with the investigation, authorities said at the Tuesday news briefing. White had no known criminal history, Hosey said. 3 Patrick Joseph Smith fired more than 180 shots into the CDC campus in Atlanta and broke 150 windows on Friday. AP Executing a search warrant at the family's home in the Atlanta suburb of Kennesaw, authorities recovered written documents that are being analyzed, and seized electronic devices that are undergoing a forensic examination, the agency said. Advertisement Investigators also recovered a total of five firearms, including a gun that belonged to his father that he used in the attack, Hosey said. Hosey said the suspect did not have a key to the gun safe: 'He broke into it,' he said. White had been stopped by CDC security guards before driving to a pharmacy across the street, where he opened fire from a sidewalk, authorities said. The bullets pierced 'blast-resistant' windows across the campus, pinning employees down during the barrage. More than 500 shell casings have been recovered from the crime scene, the GBI said. In the aftermath, officials at the CDC are assessing the security of the campus and making sure they notify officials of any new threats. Advertisement 3 Police vehiles near Emory University and the CDC campus in Atlanta after the shooting on Aug. 8, 2025. Getty Images U.S. Health Secretary Robert F. Kennedy Jr. toured the CDC campus on Monday, accompanied by Deputy Secretary Jim O'Neill and CDC Director Susan Monarez, according to a health agency statement. 'No one should face violence while working to protect the health of others,' Kennedy said in a statement Saturday. It said top federal health officials are 'actively supporting CDC staff.' Kennedy also visited the DeKalb County Police Department, and later met privately with the slain officer's wife. A photo of the suspect will be released later Tuesday, Hosey said, but he encouraged the public to remember the face of the officer instead. Kennedy was a leader in a national anti-vaccine movement before President Donald Trump selected him to oversee federal health agencies, and has made false and misleading statements about the safety and effectiveness of COVID-19 shots and other vaccines. Some unionized CDC employees called for more protections. Some employees who recently left the agency as the Trump administration pursues widespread layoffs, meanwhile, squarely blamed Kennedy. Years of false rhetoric about vaccines and public health was bound to 'take a toll on people's mental health,' and 'leads to violence,' said Tim Young, a CDC employee who retired in April.
NBC News
an hour ago
- NBC News
Atlanta gunman fired hundreds of rounds at CDC headquarters
Investigators released new details on the shooting targeting the Centers for Disease Control. Officials say Patrick Joseph White had expressed "discontent" with the Covid-19 vaccine and fired hundreds of rounds at CDC headquarters before he died by 12, 2025
Epoch Times
an hour ago
- Epoch Times
Chinese Authorities Mandating Blood Tests, Releasing Lab Mosquitoes to Fight Chikungunya Outbreak
As the chikungunya outbreak continues to spread in China, the prevention and control measures imposed by the Chinese communist regime have been causing increasing concerns among medical professionals and the Chinese public. Guangdong Province reported 1,387 new chikungunya cases in the past week (Aug. 3 to Aug. 9), according to a notice by the provincial Centers for Disease Control and Prevention. There have been no deaths from the virus reported so far, according to the Chinese agency. According to state media, as of July 29, the cumulative number of chikungunya cases in Foshan, Guangdong—where the first cases of the outbreak were reported on July 8—had exceeded 6,000. Because of the Chinese communist regime's record of censoring data it considers to be politically sensitive—as was seen with its cover-up of COVID-19 infections and related deaths in late 2019—the true number of known chikungunya fever infections could be higher. Chikungunya fever is a viral disease mainly transmitted to humans by mosquitoes. Its symptoms are similar to those of dengue fever. Patients usually experience fever, severe joint pain, muscle pain, headache, fatigue, and rash. There is no specific antiviral treatment for chikungunya. Deaths from the disease are rare but do occur, especially among vulnerable populations such as those with underlying health conditions. Globally, as of July 2025, chikungunya fever has resulted in 90 deaths across 16 impacted countries and territories. The outbreak in China started in the hardest-hit city, Foshan. Confirmed cases have since been detected in more than 10 cities in Guangdong Province, according to the Guangdong Provincial Center for Disease Control and Prevention. The Macau Health Bureau reported a case of chikungunya fever on July 18. Hong Kong health authorities reported a case on Aug. 2. Both cases were identified as children who exhibited symptoms after returning from a trip to Foshan, according to the local health authorities. The chikungunya virus has also spread to northern China. The Beijing Center for Disease Control and Prevention issued a prevention reminder on July 22, warning of occasional cases allegedly imported to Beijing from abroad. However, Beijing officials have not released any data. The U.S. Centers for Disease Control and Prevention issued a Level 2 travel alert on Aug. 1 for China as the chikungunya virus outbreak continues its spread. Chinese doctors and residents told The Epoch Times that the chikungunya virus has spread to more places in China. A Chinese doctor whose work is related to disease prevention spoke to The Epoch Times on Aug. 10 on the condition of anonymity, out of safety concerns. The doctor said that chikungunya has spread to the megacity of Chongqing in southwest China, as well as Wuhan city in central China. A resident said in a video post on social media that chikungunya fever has spread to Hunan Province, adjacent to Guangdong, and that registration is required when purchasing any medications that treat fever. Foshan Municipal Market Supervision Bureau has introduced sales control of 47 medications for treating fever, rash, joint pain, and other symptoms caused by chikungunya in all retail pharmacies in the city, requiring registration for any sales, according to a notice it issued on Aug. 4. The Chinese regime has also imposed mandatory measures that have sparked fears of a return to the regime's draconian COVID-19 restrictions, such as mandatory self-paid quarantine and PCR testing. Local residents and medical professionals have especially expressed concerns about mandatory PCR testing of blood samples for the chikungunya virus, which the regime has been pushing in its public messaging. Mandatory Blood Draws Local residents in various locations around Guangdong Province posted on social media that mandatory blood tests are being implemented for PCR testing for chikungunya, which is different from the saliva tests for COVID-19. A patient said in a video post that after hospital staff drew three flasks of blood from him, he tested positive for chikungunya. He questioned why the hospital had to take three tubes for testing. The Chinese doctor, whose work is related to disease prevention, said that the chikungunya virus requires blood for PCR testing, as it is a blood-borne disease. 'Blood draws are also used for tertiary monitoring, and vaccine development requires the isolation of toxins from the blood, so a relatively large amount of blood needs to be drawn,' he said. A Guangzhou city resident posted on social media on Aug. 9 that Jiangnan Middle Street community office staff came to his home and demanded that the residents allow their blood to be drawn. He refused, and a group of staff repeatedly came back to demand it. Another resident in Guangdong revealed in a video post on Aug. 10 that his community office staff came at 10 p.m. to draw their blood for chikungunya PCR testing. Mainland Chinese media outlets reported that in the early morning hours of Aug. 4, community office officials in Guangdong's Zhanjiang City forcibly drew blood from two minors in the absence of their parents, sparking public outrage. 'Chinese government officials taking advantage of parents' absences to draw blood from children is a serious violation of medical ethics,' Sean Lin, assistant professor in the Biomedical Science Department at Feitian College and former U.S. Army microbiologist, told NTD, the sister media outlet of The Epoch Times, on Aug. 10. Based on the reports of such harsh actions, Lin suspects that the Chinese regime 'is concealing information about whether other pathogens are also present in this outbreak along with Chikungunya, as mosquitoes in Guangdong carry more than one infectious disease.' Lin said that the Chinese Communist Party's public health department should publish a research report as soon as possible, especially during the peak of the outbreak. 'It's easy to catch a lot of mosquitoes for research to see if there were other viruses circulating at the same time, which can spare ordinary people the pain of forced quarantine and blood tests,' he said. Mosquito Lab Breeding Program Sparks Concerns Chinese state media reported in early August that China's largest mosquito breeding facility in Huangpu District of Guangzhou city, Wolbaki, was running at full capacity and releasing 5 million specially treated male mosquitoes per week, in the hopes of them mating with the wild female mosquito population to produce unviable eggs in a population control technique known as Wolbachia transinfection—where the reproductive compatibility of male mosquitoes is altered by an infection with the common naturally occurring Wolbachia bacterium. Wolbaki's founder was the former director of the Joint Center of Vector Control for Tropical Diseases, another mosquito breeding facility, at Guangzhou's Sun Yat-sen University, in partnership with Michigan State University, where Xi is a professor of microbiology, genetics, and immunology. 'When the [infected] male mosquitoes carrying the Wolbachia bacterium mate with wild female mosquitoes that do not carry the bacteria, the eggs produced cannot develop normally due to cytoplasmic incompatibility and cannot hatch into mosquito larvae,' Gong Juntao, the head researcher at Guangdong's Wolbaki company that produces the mosquitoes, told Chinese media. However, the method has loopholes, as if infected lab females are not separated and instead released into the wild, they can continue to successfully breed and spread disease. The company claims to have developed an automated technology to efficiently separate male from female lab-bred mosquito pupae, with an error rate of less than 0.5 percent. But Lin said that given the huge number of mosquitoes released, an error rate of 0.5 percent 'means there are still about 25,000 female mosquitoes that can transmit diseases being released every week.' In May, Chinese media reported that China's biggest mosquito breeding facility in Huangpu District of Guangzhou, which it referred to as only the China mosquito research center, was running a pilot study to produce 30 million Wolbachia-infected male mosquitoes—sustained on sheep's blood—to release every month as part of the authorities' disease-prevention efforts targeting the mosquito-borne dengue, Zika, and chikungunya viruses. Two months later, China saw its biggest chikungunya outbreak on record. China's efforts to curb the reproduction of wild mosquitoes through mass-produced lab males infected with Wolbachia 'has failed two rounds,' the Chinese doctor told The Epoch Times. He predicted that in southern and north-central China, the number of mosquitoes carrying the chikungunya virus will rapidly increase before winter.
